ino-5401
ino-5401: developed by 1 company · 3 clinical trials tracked.
ino-5401 evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could ino-5401 → INO affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| INOVIO PHARMACEUTICALS, INC. (INO) Urothelial Carcinoma; Glioblastoma | Phase 1/Phase 2 |
Clinical Trials (3)
Phase 1b Study of INO-5401 Alone or INO-5401 in Combination With INO-9012 Followed by Electroporation in Adult Cancer and Non-Cancer Patients With BRCA1 or BRCA2 Mutations
Primary endpoint: Dose Limiting Toxicities
An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)
Primary endpoint: Percentage of Participants with Adverse Events (AEs)
An Open-Label, Multi-Center Trial of INO-5401 + INO-9012 in Combination With Atezolizumab in Subjects With Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
Primary endpoint: Number of Adverse Events
Frequently asked questions
Who is developing ino-5401?
ino-5401 is being developed by INOVIO PHARMACEUTICALS, INC..
How many clinical trials involve ino-5401?
BioSniper tracks 3 clinical trials involving ino-5401.